Brief: Nls Pharmaceutics Announces Positive Results From Study Ko-943 Demonstrating Mazindol Reduces Fentanyl-Induced Reward In Animal Models
15/04/2025 14:13
April 15 (Reuters) - Kadimastem Ltd KDST.TA: NLS PHARMACEUTICS ANNOUNCES POSITIVE RESULTS FROM STUDY KO-943 DEMONSTRATING MAZINDOL REDUCES FENTANYL-INDUCED REWARD IN ANIMAL MODELS Source text: ID:nPn53Yxtfa Further company coverage: KDST.TA ((Reuters.Briefs@thomsonreuters.com;))
Recent news on NewcelX AG
See all newsBrief: Newcelx Announces Pricing Of $1.4 Million Equity Financing At 20% Premium Pricing
Brief: Newcelx Submits Pre-IND Package To FDA For NCEL-101 For Treatment Of Type 1 Diabetes
Brief: Newcelx Updates Corporate Presentation To Highlight Type 1 Diabetes Flagship Program
U.S. STOCKS ON THE MOVE-Eli Lilly, Space stocks, Anixa Biosciences
U.S. STOCKS ON THE MOVE-Intel, Tempus AI, Boeing